TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10827161
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of interferon‐alfa (6 MU subcutaneously 3 times weekly for 6 months followed by 3 MU for 6 months) and ribavirin (for 4, 6, or 12 months) in group C (n=129)
Study: 10827161
Drug: Interferon‐alfa alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon‐alfa alone (12‐month course with high initial doses) in group A (n=95)
Study: 8853768
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate 800 mg b.d. plus antibiotics (amoxycillin, metronidazole, clarithromycin, cefuroxime axetil, tetracycline, tetracycline plus metronidazole, or clarithromycin plus tetracycline) for 14 days
Study: 30675515
Drug: Abemaciclib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abemaciclib plus nonsteroidal aromatase inhibitor (AI)
Study: 30675515
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus nonsteroidal aromatase inhibitor (AI)
Study: 24603217
Drug: Moderate dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate dose statin (atorvastatin 10 mg/d or equivalent, n=675)
Study: 24603217
Drug: Intensive dose
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive dose statin (atorvastatin 20 or 40 mg/d or equivalent, n=680)
Study: 24603217
Drug: Moderate dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate dose statin
Study: 24603217
Drug: Intensive dose
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive dose statin
Study: 22066819
Drug: Dark chocolate
Normalized name: Ensure Original Dark Chocolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dark chocolate (40 g, cocoa > 85%)
Study: 12126459
Drug: efavirenz 600
Normalized name: efavirenz 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: efavirenz 600 mg once daily without rifampicin (group A)
Study: 12126459
Drug: efavirenz 800
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: efavirenz 800 mg once daily with rifampicin (group A-2)
Study: 12126459
Drug: rifampicin in
Normalized name: Product containing rifampicin in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rifampicin in bodyweight‐adjusted fixed‐dose combination (group B)
Study: 10428251
Drug: Self-administered tampon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered tampon before physician-directed swabs of the cervix
Study: 10428251
Drug: Physician-directed swab
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician-directed swab testing before using the self-administered tampon
Study: 7595108
Drug: Spinal manipulation
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal manipulation therapy (SMT) applied by experienced physicians
Study: 7595108
Drug: Spinal manipulation
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal manipulation therapy (SMT) applied by novice manipulators
Study: 2197004
Drug: 1.5 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg.kg‐1 intramuscular codeine
Study: 2197004
Drug: 4 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg.kg‐1 of ten per cent aerosol lidocaine
Study: 7196885
Drug: Levamisole, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole, 150 mg daily for 2 consecutive days per week for 6 weeks (Group I, half received levamisole, half received placebo)
Study: 7196885
Drug: Levamisole, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole, 150 mg daily for 2 consecutive days per week for 6 weeks (Group II, all received levamisole)
Study: 29616621
Drug: Prototype disinfectant
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prototype disinfectant spray (0.13% w/v benzalkonium chloride and a cooling agent)
Study: 29616621
Drug: BACTROBAN® disinfectant
Approvals — FDA: no, EMA: no, PMDA: no
Description: BACTROBAN® disinfectant spray
Study: 22089205
Drug: 250 mL
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mL 7.2% NaCl/6% hydroxyethyl starch (HT group)
Study: 22089205
Drug: 500 mL
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mL 6% hydroxyethyl starch (IT group)
Study: 19737845
Drug: Pharmacological therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological therapies for control of glycemia, hyperlipidemia, and hypertension (ACCORD)
Study: 3898976
Drug: Metronidazole 400
Normalized name: metronidazole 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 400 mg three times daily for 7 days
Study: 9449871
Drug: Placebo three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo three times daily for 7 days
Study: 2651509
Drug: Sustained-release terbutaline,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release terbutaline, 10 mg twice daily (b.i.d.)
Study: 2651509
Drug: Sustained-release terbutaline,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release terbutaline, 10 mg b.i.d. and two puffs (400 micrograms) of budesonide, b.i.d.
Study: 1093481
Drug: Miconazole nitrate
Normalized name: Miconazole Nitrate
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Miconazole nitrate (2.0%) cream
Study: 28939567
Drug: Prehospital administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prehospital administration of 180 mg ticagrelor
Study: 28939567
Drug: In-hospital administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-hospital administration of 180 mg ticagrelor
Study: 17397949
Drug: Pyridostigmine (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridostigmine (45 mg p.o.)
Study: 12807346
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of D-camphor and extract from fresh crataegus berries (CCC)
Study: 9551417
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment B (on-line conductivity ultrafiltrate kinetic modeling)
Study: 9551417
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment A (standard treatment with fixed dialysate conductivity)
Study: 3288866
Drug: Oral IgA-IgG
Normalized name: Igalmi Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral IgA-IgG (73% IgA and 26% IgG)
Study: 3288866
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no oral IgA-IgG)
Study: 31209851
Drug: Topical Adapalene
Normalized name: adapalene Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Adapalene 0.3%/Benzoyl Peroxide 2.5% Gel (A0.3/BPO2.5) for 48 weeks
Study: 28438596
Drug: Dexamethasone (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.1 mg/kg)
Study: 21819552
Drug: Knowledge of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Knowledge of BP treatment thresholds in CKD
Study: 21819552
Drug: Knowledge of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Knowledge of BP treatment thresholds when proteinuria is factored in
Study: 21819552
Drug: Achievement of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Achievement of P4P targets in patients treated with angiotensin modulating drugs
Study: 24200407
Drug: Prolonged conservative
Normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged conservative treatment
Study: 15143910
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg i.v. once daily (n=72)
Study: 15143910
Drug: Famotidine 40
Normalized name: famotidine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 40 mg twice a day (n=71)
Study: 15143910
Drug: Sucralfate 1
Normalized name: sucralfate 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate 1 g every 6 hours (n=69)
Study: 9257757
Drug: Levofloxacin (350
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin (350 mg of levofloxacin hemihydrate)
Study: 27918189
Drug: Mentalization-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mentalization-based therapy for parental conflict (Parenting Together)
Study: 25250291
Drug: 5% dapsone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% dapsone gel plus oral isotretinoin 20 mg daily
Study: 25250291
Drug: Oral isotretinoin
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral isotretinoin 20 mg daily (Control group with vehicle gel)
Study: 24377217
Drug: Rehabilitation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rehabilitation therapy
Study: 16882819
Drug: Fluticasone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone (2 mg via metered dose inhaler in the emergency department plus 500 microg twice daily via Diskus for 10 doses after discharge)
Study: 16882819
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (2 mg/kg in the emergency department plus 5 daily doses of 1 mg/kg after discharge)
Study: 31898212
Drug: Serotonin-norepinephrine reuptake
Normalized name: serotonin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serotonin-norepinephrine reuptake inhibitors (SNRIs)
Study: 9692422
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin 7500iu
Study: 7871610
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin once daily (prophylaxis group, n = 176)
Study: 28806194
Drug: Paliperidone palmitate
Normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paliperidone palmitate 3-month (PP3M) treatment
Study: 28806194
Drug: Paliperidone palmitate
Normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paliperidone palmitate 1-month (PP1M) treatment
Study: 21565464
Drug: Modafinil (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (up to 300 mg/day)
Study: 18489665
Drug: Continuous etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Continuous etanercept treatment (50 mg twice weekly for 12 weeks, then 50 mg once weekly for 12 weeks)
Study: 18489665
Drug: Interrupted etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Interrupted etanercept treatment (single round of discontinuation and re-treatment with etanercept 50 mg once weekly for the second 12 weeks)
Study: 16717337
Drug: Double-injection axillary
Normalized name: Iva axillaris pollen
DrugBank: Iva axillaris pollen (DB10764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-injection axillary brachial plexus block
Study: 8502513
Drug: BA +
Normalized name: Ba
DrugBank: Barium (DB12481)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BA + PL (0.2 mg albuterol with placebo three times a day)
Study: 8502513
Drug: BA +
Normalized name: Ba
DrugBank: Barium (DB12481)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BA + CS (0.2 mg albuterol with budesonide three times a day)
Study: 3318423
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of nabumetone administered at night
Study: 3318423
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of nabumetone given at night
Study: 3318423
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg of naproxen in the morning and 500 mg at night
Study: 3318423
Drug: Indomethacin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (50 mg three times daily)
Study: 18086974
Drug: Chemoradiation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoradiation therapy
Study: 24912485
Drug: Standard Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Dose (SD) oseltamivir
Study: 24912485
Drug: Double Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double Dose (DD) oseltamivir
Study: 19289342
Drug: Medication Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication Therapy Management (MTM) services for hypertension and diabetes management
Study: 14998223
Drug: Erythropoietic agents
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietic agents
Study: 3236744
Drug: Topically applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topically applied dexamethasone eyedrops 0.1% with local antibiotics
Study: 3236744
Drug: Indomethacin (an
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (an inhibitor of cyclooxygenase)
Study: 26360283
Drug: Bespoke smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bespoke smoking cessation strategy (behavioural support and drugs)
Study: 24342651
Drug: Eravacycline at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eravacycline at 1.5 mg/kg q24h
Study: 24342651
Drug: Eravacycline at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eravacycline at 1.0 mg/kg q12h
Study: 24342651
Drug: Ertapenem at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertapenem at 1 g q24h
Study: 19574947
Drug: Piribedil (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piribedil (50 mg for 90 days)
Study: 17306648
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy (HRT) - conjugated estrogens 0.625 mg plus medroxyprogesterone acetate 2.5 mg
Study: 15105403
Drug: Promegetone 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promegetone 0.5 mg plus estradiol 2 mg (E) per day
Study: 15105403
Drug: Promegetone 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promegetone 0.5 mg plus estradiol placebo (PL)
Study: 8529329
Drug: Intravenous losartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous losartan
Study: 8529329
Drug: Oral losartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral losartan
Study: 2474257
Drug: 2 litres
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 litres of crystalloid solution
Study: 2474257
Drug: 1 litre
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 litre of colloid solution (hydroxyethyl starch)
Study: 9377121
Drug: Immediate antiretroviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate antiretroviral therapy
Study: 19020325
Drug: Deferred antiretroviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferred antiretroviral therapy
Study: 31416496
Drug: Progressively integrated
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Progressively integrated sandplay therapy
Study: 28917373
Drug: Topical Rosa
Normalized name: Rosa moschata oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Rosa damascena oil
Study: 21451092
Drug: Various physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various physical therapy interventions
Study: 19349712
Drug: TTS E2/MPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTS E2/MPA (transdermal estradiol 50 microg + oral medroxyprogesterone acetate 10 mg/day for 12 days)
Study: 14767865
Drug: Omacor (omega-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omacor (omega-3 polyunsaturated fatty acid concentrate) 4 capsules daily for 8 weeks
Study: 8501418
Drug: Cyclosporin (Cs)
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin (Cs) treatment at an initial dose of 10 mg kg‐1 BW day‐1 for 12 months
Study: 8501418
Drug: Cyclosporin (Cs)
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin (Cs) treatment
Study: 3519096
Drug: Low-dose trimipramine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose trimipramine (25 to 75 mg/day)
Study: 30521639
Drug: Total PBS
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total PBS anticoagulant expenditure
Study: 29231566
Drug: Moxibustion combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxibustion combined with autohemotherapy of acupoint injection
Study: 25301344
Drug: Piperacillin 4
Normalized name: piperacillin 4000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin 4 g with tazobactam 0.5 g intravenously by 1-hour infusion every 8 hours
Study: 22735756
Drug: RC-3095 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: RC-3095 (3 mg/kg, intravenous) administered over a period of 12 h in human patients with sepsis.
Study: 22735756
Drug: RC-3095 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: RC-3095 (3 mg/kg, subcutaneously) in male Wistar rats subjected to cecal ligation and puncture (CLP).
Study: 22735756
Drug: RC-3095 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: RC-3095 (10 ng/mL) in RAW 264.7 culture cells exposed to LPS or TNF-α.
Study: 15986192
Drug: 0.42 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.42 mg/kg d,l-dexamphetamine
Study: 22020992
Drug: 0.42 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.42 mg/kg d-methamphetamine
Study: 15986192
Drug: 0.42 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.42 mg/kg d,l-methamphetamine
Study: 8535711
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg epirubicin combined with 10 MU alpha 2b‐IFN, intravesically in 50 mL sterile buffer solution
Study: 8535711
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg epirubicin
Study: 2243428
Drug: Combined drug
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined drug regimens and diet
Study: 30458740
Drug: Bitterant formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bitterant formulation
Study: 30458740
Drug: Perfumed formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perfumed formulation
Study: 30458740
Drug: Plain formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain formulation
Study: 27585777
Drug: 50-ppm sodium
Normalized name: HYPOCHLOROUS ACID 50 [ppm] in 1 mL / SILVER 8 [ppm] in 1 mL TOPICAL SPRAY [OXICLEANSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50-ppm sodium fluoride solution
Study: 23724518
Drug: Gonadotropin treatment
Normalized name: Chorionic Gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonadotropin treatment and letrozole along with GnRH antagonist protocol (Group 1)
Study: 23724518
Drug: Gonadotropin treatment
Normalized name: Chorionic Gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonadotropin treatment along with GnRH antagonist protocol (Group 2)
Study: 18721002
Drug: Cinacalcet 90
Normalized name: cinacalcet 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinacalcet 90 mg once daily for 5 days
Study: 18721002
Drug: Midazolam 2
Normalized name: midazolam 2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 2 mg alone
Study: 8824967
Drug: Single injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection of diphtheria and tetanus toxoids and pertussis vaccine combined with inactivated poliovirus vaccine
Study: 1486543
Drug: Pravastatin (hydroxymethyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (hydroxymethyl glutaryl coenzyme A reductase inhibitor)
Study: 23279614
Drug: Once-daily extended-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily extended-release tacrolimus (LCPT)
Study: 20143651
Drug: Rupatadine, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rupatadine, 20 mg/d
Study: 7503601
Drug: Low-dose amphotericin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose amphotericin B (total dose ≤ 500 mg)
Study: 7503601
Drug: High-dose amphotericin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose amphotericin B (total dose > 500 mg)
Study: 2048709
Drug: Droperidol 0.075
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 0.075 mg/kg i.v. given at induction of anesthesia after intubation (n = 20)
Study: 2048709
Drug: Droperidol 0.075
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 0.075 mg/kg i.v. given during the last muscle suture (n = 21)
Study: 2048709
Drug: No antiemetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antiemetic treatment (n = 20)
Study: 6793303
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of prostaglandin F2 alpha (PGF2 alpha)
Study: 6793303
Drug: Oral quinine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral quinine hydrochloride
Study: 24086259
Drug: Serogroup-C-meningococcal-conjugate-vaccine (partly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serogroup-C-meningococcal-conjugate-vaccine (partly vaccinated villages)
Study: 19694438
Drug: Yerba mate
Normalized name: yerba mate
DrugBank: Ilex paraguariensis leaf (DB14366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yerba mate consumption (330 mL, 3 times/day for 40 days) in normolipidemic subjects
Study: 19694438
Drug: Yerba mate
Normalized name: yerba mate
DrugBank: Ilex paraguariensis leaf (DB14366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yerba mate intake by dyslipidemic individuals (330 mL, 3 times/day for 40 days)
Study: 19694438
Drug: Yerba mate
Normalized name: yerba mate
DrugBank: Ilex paraguariensis leaf (DB14366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yerba mate consumption by hypercholesterolemic individuals on statin therapy (330 mL, 3 times/day for 40 days)
Study: 17240472
Drug: Telmisartan (20-40mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan (20-40mg orally once daily for 6 months)
Study: 3267741
Drug: Group therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group therapy (10 sessions of 90 minutes each, led by a psychologist and a general practitioner)
Study: 31868550
Drug: 0.25ug alfacalcidol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25ug alfacalcidol daily for 3 months